Latest Regulatory Risk News

BlinkLab Limited reported a substantial net loss of $5.7 million for FY2025, driven by intensive R&D and clinical trial activities, while securing $7.66 million in fresh capital to fuel its smartphone-based neurodevelopmental diagnostic platform targeting autism and ADHD.

NeuroScientific Biopharmaceuticals reported a $1.85 million loss for FY25, driven by reduced R&D incentives and increased development costs following its acquisition of StemSmart™ technology. The company is advancing clinical programs, including a Special Access Scheme for Crohn’s disease.

Helix Resources Limited’s HLXOA securities have been suspended from trading pending regulatory compliance, raising questions about the company’s immediate outlook.

Solvar Limited’s FY25 results highlight solid loan book growth in Australia, the strategic launch of Bennji commercial finance, and a significant 40% increase in dividends, underpinning confidence in future earnings.

Clinuvel Pharmaceuticals has reported a robust financial year ending June 2025, marked by solid revenue growth and sustained profitability, while advancing its clinical pipeline and maintaining a strong balance sheet.

Zoono Group Limited reported a 19.1% revenue increase to NZ$1.25 million for FY2025, alongside a significantly reduced net loss. The company is pivoting towards B2B markets, focusing on antimicrobial and shelf-life extension technologies, supported by a recent AUD 1.78 million capital raise.

Perpetual Limited reported a steady FY25 with underlying profit after tax of $204.1 million, revenue growth across all segments, and a net loss narrowed to $58.2 million. The firm’s refreshed strategy focuses on simplification, operational excellence, and measured growth investments amid evolving regulatory landscapes.

Micro-X Limited reported a $13.9 million loss for FY2025 as it pivots towards medical imaging, securing a landmark supply agreement with a major US healthcare provider for its Rover Plus mobile X-ray system.

Qantas Airways posted a robust FY25 financial performance with a 28% rise in statutory profit after tax, supported by strong travel demand and strategic fleet investments. The Group also announced substantial dividends and completed a $431 million share buy-back, while closing Jetstar Asia to focus on core markets.

Atlas Arteria reported an 11.4% rise in revenue for the half year ended June 2025, driven by toll growth across its global portfolio. However, net profit fell 32.9% due to a one-off French tax and ongoing challenges in the US.

Medibank Private Limited reported steady revenue growth and stable profit for FY25, while navigating ongoing cybercrime-related expenses and regulatory scrutiny. The insurer also announced increased dividends and outlined strategic investments in health services and digital transformation.

Mineral Resources Limited posted a $896 million statutory loss for FY25, driven by significant impairments, while Onslow Iron achieved commercial production and governance reforms reshape the board.